InnoCare to Buy Remaining Stake in Life Sciences Subsidiary for 476 Million Yuan; Shares Down 9%

MT Newswires Live

Aug 20

InnoCare Pharma (SHA:688428, HKG:9969) plans to acquire the remaining 7% stake it does not yet hold in its subsidiary, Guangzhou InnoCare Pharma Technology, for up to 476.3 million yuan, according to a Shanghai bourse disclosure on Wednesday.

The stake of the life sciences company will be bought from Guangzhou High-tech Zone Technology Holding Group.

The pharmaceutical company will fully own Guangzhou InnoCare after the completion of the transaction.

InnoCare's Shanghai shares dropped less than 9%, and Hong Kong shares slumped over 8% during midday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2560125822"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560125822\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560125822?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-20 12:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560125822","market":"sg","top_or_hot":-1,"title":"InnoCare to Buy Remaining Stake in Life Sciences Subsidiary for 476 Million Yuan; Shares Down 9%","media":"MT Newswires Live","content":"<html><body><p> InnoCare Pharma (SHA:688428, HKG:9969) plans to acquire the remaining 7% stake it does not yet hold in its subsidiary, Guangzhou InnoCare Pharma Technology, for up to 476.3 million yuan, according to a Shanghai bourse disclosure on Wednesday.</p><p>The stake of the life sciences company will be bought from Guangzhou High-tech Zone Technology Holding Group.</p><p>The pharmaceutical company will fully own Guangzhou InnoCare after the completion of the transaction.</p><p>InnoCare's Shanghai shares dropped less than 9%, and Hong Kong shares slumped over 8% during midday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InnoCare to Buy Remaining Stake in Life Sciences Subsidiary for 476 Million Yuan; Shares Down 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnoCare to Buy Remaining Stake in Life Sciences Subsidiary for 476 Million Yuan; Shares Down 9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-20 12:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> InnoCare Pharma (SHA:688428, HKG:9969) plans to acquire the remaining 7% stake it does not yet hold in its subsidiary, Guangzhou InnoCare Pharma Technology, for up to 476.3 million yuan, according to a Shanghai bourse disclosure on Wednesday.</p><p>The stake of the life sciences company will be bought from Guangzhou High-tech Zone Technology Holding Group.</p><p>The pharmaceutical company will fully own Guangzhou InnoCare after the completion of the transaction.</p><p>InnoCare's Shanghai shares dropped less than 9%, and Hong Kong shares slumped over 8% during midday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2560125822","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560125822","pubTimestamp":1755663591,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"InnoCare Pharma (SHA:688428, HKG:9969) plans to acquire the remaining 7% stake it does not yet hold in its subsidiary, Guangzhou InnoCare Pharma Technology, for up to 476.3 million yuan, according to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK1161":"生物科技","BK1574":"生物医药B类股","09969":"诺诚健华","BK0239":"医药制造"},"translate_title":"诺诚健华将以4.76亿元收购生命科学子公司剩余股权；股价下跌9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":0.9,"09969":0.9},"content_text":"InnoCare Pharma (SHA:688428, HKG:9969) plans to acquire the remaining 7% stake it does not yet hold in its subsidiary, Guangzhou InnoCare Pharma Technology, for up to 476.3 million yuan, according to a Shanghai bourse disclosure on Wednesday.The stake of the life sciences company will be bought from Guangzhou High-tech Zone Technology Holding Group.The pharmaceutical company will fully own Guangzhou InnoCare after the completion of the transaction.InnoCare's Shanghai shares dropped less than 9%, and Hong Kong shares slumped over 8% during midday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}